Zachary Veitch

Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies

John Hilton, Karen A. Gelmon, Philippe L. Bédard et al. · Nature Communications · 2022 · 145 citations · Full text

Life Sciences, Molecular Biology, Oncology +15

Role of drug transporters and drug accumulation in the temporal acquisition of drug resistance

Stacey L. Hembruff, Monique L. Laberge, David J. Villeneuve et al. · BMC Cancer · 2008 · 83 citations · Full text

Medicine, Cancer Biology, Pharmacology +16

Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial

Zachary Veitch, David W. Cescon, Trisha A. Denny et al. · British Journal of Cancer · 2019 · 69 citations · Full text

Medicine, Oncology, Pharmacology +16

cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance

David J. Villeneuve, Stacey L. Hembruff, Zachary Veitch et al. · Breast Cancer Research and Treatment · 2005 · 55 citations

Medicine, Molecular Genetics, Oncology +12

Induction of 1C aldoketoreductases and other drug dose-dependent genes upon acquisition of anthracycline resistance

Zachary Veitch, Baoqing Guo, Stacey L. Hembruff et al. · Pharmacogenetics and Genomics · 2009 · 55 citations

Medicine, Oncology, Pharmacology +15